ISSN 2415-3060 (print), ISSN 2522-4972 (online)
JMBS
  • 18 of 44
Up
JMBS 2019, 4(2): 122–128
https://doi.org/10.26693/jmbs04.02.122
Clinical Medicine

Using Bretshnader Solution for Pharmaco-Cold Cardioplegic Protection of Myocardium during Coronary Artery Bypass Grafting

Druzhyna O. M. 1,2, Dziuba D. O. 2, Loskutov O. A. 1,2, Maruniak S. R. 1,2
Abstract

Postoperative hemodynamic disturbances during surgery with cardiopulmonary bypass can account for 70% of cases. This statistics is largely due to the inconsistency of myocardial protection with the level of hypoxia during the main phase of the operation. The purpose of the study was to check the effectiveness of cardioprotection using Bretschneider cardioplegic solution during coronary artery bypass grafting. Material and methods. The study included 60 patients who underwent the coronary artery bypass grafting in combination with aneurysmoplasty of left ventricular. The average age was 68.96±1.81 years old. The average body weight was 86.5±1.44 kg. The coronary artery bypass grafting was performed under moderate hypothermia (the central temperature was + 30°C - +32°C). The productivity of the cardiopulmonary bypass machine during the period of perfusion was 2.4 liters / min. / m2. To assess the effectiveness of myocardial protection, we analyzed the doses of inotropic agents and the growth dynamics of the cardiospecific enzymes: MB-CPK and TnI. Results and discussion. Dopamin was used in medium doses in 49 patients (81.7%) and in small ones in 11 patients (18.3%). Adrenaline was used in small doses in 4 (6.7%) patients. In the postperfusion period, rhythm disturbances were observed in 6 supervised patients (10% of cases). The value of Troponin I was 1.68 ± 0.04 ng/ml, while MB-CPK was 6.8±0.07 MO/l and corresponded to an uncomplicated course of the postoperative period. Conclusions. Pharmaco-cold Bretschneider cardioplegic solution ensured a reliable level of cardioprotection, which was confirmed by the absence of pathological growth of cardiovascular enzymes, low need for inotropic agents and low frequency of arrhythmias.

Keywords: coronary artery bypass grafting, local cardioprotection, cardiopulmonary bypass, Bretschneider solution

Full text: PDF (Ukr) 245K

References
  1. Loskutov OA. Sravnytelnaya kharakterystyka kardyoprotektornogo deystvyya yskusstvennoy elektrycheskoy fybryllyatsyy serdtsa y rastvora Bretshnaydera pry operatsyyakh aortokoronarnogo shuntyrovanyya. Visnyk problem biologiyi i medytsyny. 2013; 1: 125–8. [Russian]
  2. Ustynov AV. Kardyokhyrurgyya y ynterventsyonnaya kardyologyya: problemy y perspektyvy razvytyya. Ukrayinskyy medychnyy chasopys. 2012; 1(87): 8–10. [Russian]
  3. Hannan EL, Zhong Y, Lahey SJ, Culliford AT, Gold JP, Smith CR, et al. 30-day readmissions after coronary artery bypass graft surgery in New York State. JACC Cardiovasc Interv. 2011; 4(5): 569–76. https://www.ncbi.nlm.nih.gov/pubmed/21596331. https://doi.org/10.1016/j.jcin.2011.01.010
  4. Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, et al. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. Circulation. 2006; 113(18): 2177–85. https://www.ncbi.nlm.nih.gov/pubmed/16651468. https://doi.org/10.1161/CIRCULATIONAHA.105.610352
  5. Øvrum E, Tangen G, Tølløfsrud S, Øystese R, Ringdal MA, Istad R. Cold blood cardioplegia versus cold crystalloid cardioplegia: a prospective randomized study of 1440 patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004; 128(6): 860–5. https://www.ncbi.nlm.nih.gov/pubmed/15573070. https://doi.org/10.1016/j.jtcvs.2004.03.032
  6. Zeng J, He W, Qu Z, Tang Y, Zhou Q, Zhang B. Cold blood versus crystalloid cardioplegia for myocardial protection in adult cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2014; 28(3): 674–81. https://www.ncbi.nlm.nih.gov/pubmed/24721161. https://doi.org/10.1053/j.jvca.2013.06.005
  7. Alwaqfi NR, Khader YS, Ibrahim KS, Eqab FM. Coronary artery bypass grafting: 30-day operative morbidity analysis in 1046 patients. J Clin Med Res. 2012; 4(4): 267–73. https://www.ncbi.nlm.nih.gov/pubmed/22870174. https://www.ncbi.nlm.nih.gov/pmc/articles/3409622. https://doi.org/10.4021/jocmr1020w
  8. Berdowski J, Berg RA, Tijssen JG, Koster RW. Global incidences of out-of- hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. Resuscitation. 2010; 81(11): 1479–87. https://www.ncbi.nlm.nih.gov/pubmed/20828914. https://doi.org/10.1016/j.resuscitation.2010.08.006
  9. Hausenloy DJ, Boston-Griffiths E, Yellon DM. Cardioprotection during cardiac surgery. Cardiovasc Res. 2012; 94(2): 253–65. https://www.ncbi.nlm.nih.gov/pubmed/22440888. https://www.ncbi.nlm.nih.gov/pmc/articles/3331616. https://doi.org/10.1093/cvr/cvs131
  10. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and strok estatistics – 2011 update: A report from the american heart. Circulation. 2011; 123(4): e18–e209. https://www.ncbi.nlm.nih.gov/pubmed/21160056. https://www.ncbi.nlm.nih.gov/pmc/articles/4418670. https://doi.org/10.1161/CIR.0b013e3182009701
  11. Kinoshita T, Asai T. Preservation of myocardium during coronary artery bypass surgery. Curr Cardiol Rep. 2012; 14(4): 418–23. https://www.ncbi.nlm.nih.gov/pubmed/22528557. https://doi.org/10.1007/s11886-012-0271-0
  12. Macedo FI, Rodriguez Y, Salerno TA. Myocardial preservation: beating heart techniques. Semin Thorac Cardiovasc Surg. 2011; 23(4): 314–7. https://www.ncbi.nlm.nih.gov/pubmed/22443651. https://doi.org/10.1053/j.semtcvs.2011.12.007
  13. Korun O, Özkan M, Terzi A, Aşkın G, Sezgin A, Aşlamacı S. The comparison of the effects of Bretschneider's histidine-tryptophan-ketoglutarate and conventional crystalloid cardioplegia on pediatric myocardium at tissue level. Artif Organs. 2013; 37(1): 76–8. https://www.ncbi.nlm.nih.gov/pubmed/23305576. https://doi.org/10.1111/j.1525-1594.2012.01575.x